Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II non-randomized, open, uncontrolled and bi-centric study of hormonal
induction by exemestane (Aromasin) + tamoxifen to evaluate the effectiveness of exemestane
(Aromasin) with tamoxifen on the rate of clinical response menopausal in patients with tumors
of locally advanced breast. Hormone therapy will be administered at a dose of 25mg/day for
exemestane and 20 mg / day for 4 months for tamoxifen.